Older Adults Struggle to Get Pfizer’s $225,000-a-Year Heart Drug
- Pfizer medication price seen as a barrier to some patients
- Among 50 patients, some paid thousands, others didn’t get it
This article is for subscribers only.
Pfizer Inc.’s new $225,000-a-year heart drug is being labeled by researchers critical of the cost as “the most expensive cardiac medication in history.”
When the company initially priced the drug, called tafamidis, critics warned the high cost would present a prohibitive financial barrier to some patients. A new analysis that hones in on 50 people prescribed the medication offers data suggesting that may be true for many patients.